COMPANY

Bolt Biotherapeutics

HQ: Redwood City, CA source · boltbio.com ↗

Keywords: oncology antibody monoclonal antibody cancer HER2-positive Breast Cancer Gastric Cancer Adenocarcinoma Metastatic Gastroesophageal Adenocarcinoma Metastatic Breast Cancer Triple Negative Breast Cancer Clear Cell Renal Cell Carcinoma Ovarian Cancer Head and Neck Cancer Colorectal Cancer Non-small Cell Lung Cancer Melanoma HER2-positive Solid Tumors HER2-positive Colorectal Cancer HER2-positive Gastroesophageal Cancer HER2-positive Endometrial Cancer BDC-1001 BDC-4182 BDC-3042

Location: Redwood City, CA · source · Oct 14, 2026

Profile checked Oct 10, 2026

4Trials (company is sponsor)

Timeline

May 26, 2025 Trial start Phase 1/Phase 2: A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer source ↗
Nov 30, 2023 Trial start Phase 2: Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer source ↗
Oct 11, 2023 Trial start Phase 1: Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies source ↗
Feb 24, 2020 Trial start Phase 1/Phase 2: A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors source ↗

Upcoming milestones

2027-05 (ESTIMATED) · Phase 1/Phase 2 · A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer · NCT06921837

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 4

Record	Title	Phase	Status	Start	Primary completion
NCT06921837	A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer	Phase 1/Phase 2	Recruiting	May 26, 2025	2027-05 (estimated)
NCT05954143	Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer	Phase 2	Terminated	Nov 30, 2023	Sep 20, 2024 (actual)
NCT06052852	Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies	Phase 1	Terminated	Oct 11, 2023	Aug 1, 2025 (actual)
NCT04278144	A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors	Phase 1/Phase 2	Terminated	Feb 24, 2020	Dec 10, 2024 (actual)